VJHemOnc Podcast
iwAL 2022 Session III: novel targets, combinations and treatment strategies in AML
Nov 16, 2022
Experts Richard Stone and David Sallman discuss novel targets, combinations, and treatment strategies in AML. They explore the potential of drugs Eptenoprop and Magrolumab for TP53-mutated AML, and the importance of mature data sets and specific population focus in phase three trials. The use of complete remission rate as a primary endpoint for TP53 mutant patients is questioned, and CD47 inhibition as a potential therapy is explored.
12:56
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- P53 refolding agents like Eptenoprop and Magrolumab show promise in treating AML, with response rates of around 70% and overall survival at 12 months in phase two studies, but future efficacy remains uncertain due to negative phase three trials in MDS.
- Combination studies with Magrolumab and other agents like Venetoclax have demonstrated promising response rates in TP53 AML patients, highlighting their potential as an interesting option to target TP53 mutated patients.
Deep dives
Development of P53 refolding agents in AML
Experts discuss the potential of P53 refolding agents in treating AML, particularly focusing on drugs like Eptenoprop and Magrolumab. Phase two studies showed promising results with response rates of around 70% and overall survival at 12 months. Some patients even achieved deep CR before transplantation. However, phase three trials in MDS were negative, raising questions about the future of these drugs. Combination studies with other agents like Venetoclax showed promising response rates in TP53 AML patients, making them a potential interesting option to target TP53 mutated patients.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
